VJHemOnc Podcast

Explore the impact of the tumor microenvironment on immunotherapy for non-Hodgkin lymphoma. Discuss optimized conditions for developing follicular lymphoma and potential therapies targeting the CCL1 receptor. Learn about factors influencing response to T-cell therapy, including combination approaches and suppressive myeloid cells. Discover strong response rates and novel combinations in DLBCL treatment. Explore the development of novel immunomide drugs for B-cell lymphomas and ongoing clinical trials.

Discussion on the latest updates and research in multiple myeloma, including the promising results of the Myeloma trial, the use of subcutaneous DERA in treatment, advancements in treating high-risk patients, implications of the CASAPIRA trial, and the latest developments in CAR T-cell therapy.

Discover the latest updates from clinical trials investigating novel therapies for myelofibrosis, including the benefits of Pelopressi and the importance of JAK inhibitor therapies. Learn about the findings from the Jakarta trials and the long-term survival benefit of Ruxolitinib and Vidoclax in combination.

Experts discuss highlights from EHA and ASCO 2021, including novel JAK inhibitors, therapies for rarer MPNs, and updates from Phase III trials. They explore Jack inhibitors' benefits, personalized treatment, and potential combination therapies. The potential treatment PTG 300 for polycythemia vera and progress in ET are also covered. The update on ABAPrydenib in rare diseases and its safety and efficacy is discussed. The importance of survival as the primary endpoint in MPN clinical trials and the future of MPN treatments are highlighted.

Renowned experts discuss exciting developments in the MDS space reported at the ASCO and EHA 2021 meetings. Topics include latest trial data, novel targets and therapeutics, PIVONATI study, durability of McGrollumab, challenges with using MCL1 inhibitors, and agents targeting CD47.

The podcast discusses fixed-duration therapy in CLL, highlighting the advantages of shorter treatment times and lower costs. Ongoing trials will determine the best drug combinations and patient populations. The optimal treatment selection and sequencing of therapies in the era of targeted therapies is also explored. Updates on the Phase 2 Captivate Trial show positive results with Ibrutinib plus Venetoclax. A phase 3 study comparing ibrutinib and venetoclax to chlorambucil in elderly patients with CLL demonstrates improved outcomes. Sequencing of targeted therapies in CLL is discussed, emphasizing the need for further data.

Experts discuss recent developments in AML including targeted therapeutic agents, MRD approaches, and emerging therapies. Updates on guilt-retinib combinations and NGS-based MRD techniques. Importance of sequential NGS monitoring in AML and potential of IDH inhibitors with HMA therapy. Results of oral asus in combination with chemotherapy for MPM1 positive patients. Development of immunotherapy approaches for AML and MDS, including CD47 pathway and CAR-T therapy.

Experts discuss key trial updates in myeloma, including novel therapies, monoclonal antibodies, CAR-T therapies, and the need for new treatments. Updates on ticlister map, Mervufen combination therapy, Tauqueta map, and the Dario trial on exasumab and dexamethasone.

Experts discuss key updates and future directions for CAR-T therapy in acute lymphoblastic leukemia (ALL), including allergenic CAR-T cells, clinical trials, targeting strategies, cytokine release syndrome, neurotoxicity, and approaches to reduce neurotoxicity.

Myeloma patients and advocates discuss the challenges faced during the COVID-19 pandemic, including the transition to virtual support groups and the role of advocacy groups. Positive impacts of virtual meetings and concerns for technologically disadvantaged patients are highlighted. Changes in work and patient consultations, benefits of telemedicine, and the importance of patient input in research are discussed. Speakers express gratitude and support for myeloma patients.